Johnson & JohnsonNYSE: JNJ

Lately, users of Zacks.com have been focusing on Johnson & Johnson (JNJ). This interest prompts a closer look at what the stock might offer.

Over 90 presentations of clinical trial and real-world data showcase important evidence that could change medical practices and demonstrate a commitment to developing new treatments for patients with blood cancers. Johnson & Johnson announced that these abstracts will be shared at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, taking place from December 7-10.

On Monday, Johnson & Johnson announced that their medication for a specific skin condition achieved its primary objectives in a late-stage trial.

ICONIC-LEAD met its main goals, with 74% of patients showing clear or nearly clear skin by week 24. Meanwhile, ICONIC-TOTAL also reached its primary goal of an IGA score of 0 or 1 at week 16 for patients with hard-to-treat plaque psoriasis. Protagonist Therapeutics has received a $165 million milestone payment as part of their agreement with Johnson & Johnson for these successful studies.

Johnson & Johnson (NYSE:JNJ) will be participating in the Stifel 2024 Healthcare Conference on November 18, 2024, at 10:55 AM ET. Michael Bodner, the Group President of Heart Recovery and Circulatory Restoration, will represent the company. Rick Wise from Stifel is hosting the event and is excited to welcome J&J.

The CHMP's recommendation relies on data from advanced studies, indicating that JNJ's combination medication lowers the chance of disease worsening or death by 30% in specific patients with NSCLC.

Johnson & Johnson (NYSE:JNJ) will participate in the Guggenheim Global Healthcare Conference on November 12, 2024, at 10:30 AM ET. The company representatives include Biljana Naumovic, Worldwide VP of Global Commercial Strategy for Oncology, and Mark Wildgust, VP of Global Medical Affairs for Oncology. Vamil Divan from Guggenheim Securities will lead the conference call.

Currently, high inflation and high stock prices make it difficult to choose the right stocks. However, there are still some dividend stocks that are good options for the long term. These two stocks not only have the potential for growth but also help protect against inflation, providing stability and income even during market ups and downs.

Adults with moderate to severe Sjögren's disease showed improvements in their disease activity scores after 24 weeks of treatment with the investigational drug nipocalimab, which also led to a significant decrease in IgG and autoantibody levels. The U.S. FDA has given nipocalimab Breakthrough Therapy Designation for treating this condition based on findings from the Phase 2 DAHLIAS study. Johnson & Johnson shared these results at the American College of Rheumatology Convergence 2024, highlighting a reduction of over 77% in IgG levels among patients.